Latest Breaking News On - ஜேம்ஸ் ம்க்குள்ளி - Page 1 : vimarsana.com

$5M financing round led by Kizoo Technology Capital Fresh capital to be employed for productization, to prepare a clinical trial in organ transplantation and to expand cellvie s pipeline into rejuvenation therapies Promising initial clinical data generated at Boston Children s Hospital to be published in the Journal of Thoracic and Cardiovascular Surgery Zurich/Switzerland and Houston/USA, January 25, 2021: cellvie Inc., the leader in Therapeutic Mitochondria Transfer (TMT) and a Harvard University spin-off, closes a $5M round to advance its product pipeline, including a first application in rejuvenation. Mitochondria are intimately tied to the origin of complex life, the energy of the young and the decline of the old. They are the powerhouses of the cell, generating most of the cellular energy and operate as critical intra-cellular communication nodes. Mitochondria dysfunction has been tied to a host of diseases, ranging from neurodegenerative ailments such as Parkinson s and

Boston
Massachusetts
United-states
Switzerland
Harvard-university
James-mccully
Alexander-schueller
Frank-schueler
Kizoo-technology-capital
Healthy-group
Harvard-medical-school
Boston-children